| Budget Amount *help |
¥199,940,000 (Direct Cost: ¥153,800,000、Indirect Cost: ¥46,140,000)
Fiscal Year 2019: ¥39,780,000 (Direct Cost: ¥30,600,000、Indirect Cost: ¥9,180,000)
Fiscal Year 2018: ¥39,130,000 (Direct Cost: ¥30,100,000、Indirect Cost: ¥9,030,000)
Fiscal Year 2017: ¥39,390,000 (Direct Cost: ¥30,300,000、Indirect Cost: ¥9,090,000)
Fiscal Year 2016: ¥41,210,000 (Direct Cost: ¥31,700,000、Indirect Cost: ¥9,510,000)
Fiscal Year 2015: ¥40,430,000 (Direct Cost: ¥31,100,000、Indirect Cost: ¥9,330,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we aimed to elucidate the various tumor-promoting effects of TGF-β. We found that active Ras greatly affects the expression profiles of TGF-β target genes, and that it acts as a switch in the conversion of TGF-β from tumor suppressor to tumor promoter. TGF-β induces epithelial-mesenchymal transition (EMT). In this project, we found that EMT affects the expression of inflammation-related genes. Furthermore, we showed that long-term TGF-β stimulation stabilizes the EMT phenotype. Using a tissue-clearing technology, we found that TGF-β is involved in intravasation in the primary tumor as well as in the extravasation of cancer cells in the blood vessels at distant organs. In metastatic foci, TGF-β-stimulated cells contribute to the formation of metastatic niches, and TGF-β may play a critical role in the formation of metastatic colonies.
|
